Asia-Pacific Alpha-Glucosidase Inhibitors Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2018 - 2022 |
| CAGR | 2.30 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Asia-Pacific Alpha-Glucosidase Inhibitors Market Analysis
The Asia-Pacific Alpha-Glucosidase Inhibitors Market size is estimated at USD 4.14 billion in current year, and is expected to reach USD 4.64 billion by forecast year, growing at a CAGR of 2.30% during the forecast period.
People with Covid-19 had a statistically greater incidence of type 2 diabetes and other kinds of diabetes in the Asia-Pacific region. Individuals with no history of diabetes who recovered from SARS-CoV-2 infections have been reported to develop insulin resistance and reduced insulin secretion. It has been proposed that integrated rather than disease-specific methods are needed for post-Covid syndrome diagnosis and therapy.
Alpha-glucosidase inhibitors (AGIs) are a class of diabetes medications used to treat type 2 diabetes. This activity covers the indications, mechanism of action, contraindications, adverse effects, monitoring, and other critical elements needed by healthcare professionals involved in the management of type 2 diabetes mellitus and its complications. Although alpha-glucosidase inhibitors have been studied as monotherapy and as part of a combination regimen for the treatment of diabetes, they are not considered standard first-line therapy due to their low efficacy and poor tolerance. If the gastrointestinal side effects are tolerated, they may play a role as part of a combination regimen in people who consume high-carbohydrate diets and have high postprandial glucose levels.
This is driving the demand for Alpha-Glucosidase Inhibitors Market in Asia-Pacific, thereby driving the market in focus during the forecast period.
Asia-Pacific Alpha-Glucosidase Inhibitors Market Trends
Rising Diabetes Prevalence in Asia-Pacific Region
Diabetes prevalence increased alarmingly in the Asia-Pacific region in recent years. Diabetes is at an all-time high in developing countries such as China and India. By monitoring their blood glucose levels, patients with diabetes require several adjustments throughout the day to maintain normal blood glucose levels, such as oral anti-diabetic medicine or the absorption of extra carbs.
Because of the growing diabetic population in the Asia-Pacific region, China is identified as a potential developing market. China is a mature market with associated challenges, such as slow economic growth, an aging population, and increased competition. There is a growing preference for oral anti-diabetics among type 2 diabetic patients in this region, driving the market's growth under consideration. China includes the largest market share and contributes considerably to the global diabetes medicine market. The country is seeing a considerable surge in generic medicine producers.
Furthermore, the market's main global firms are encountering fierce rivalry from regional competitors. In the current year, according to Diabetes Australia, 'The Australian health system spends USD 2.5 billion per annum directly on diabetes'. On top of this, diabetes is a leading cause of heart disease, which costs the health system more than USD 2 billion per annum. There is also chronic kidney disease, which costs USD 1.7 billion, and stroke, which costs USD 660 million.
China is Expected to Dominate the Asia-Pacific Alpha-Glucosidase Inhibitors Market.
The alpha-glucosidase inhibitors (acarbose, miglitol, and voglibose) are extensively studied in China. They inhibit upper gastrointestinal enzymes (alpha-glucosidases) that convert complex polysaccharide carbohydrates into monosaccharides in a dose-dependent manner when taken orally. As a result, these drugs slow dietary carbohydrate absorption. The slower rise in postprandial blood glucose concentrations may benefit both type 1 and type 2 diabetes. Acarbose may also increase insulin sensitivity in older patients with type 2 diabetes, though this may be a nonspecific effect associated with improved glycemia. When used alone or combined with other agents that do not cause hypoglycemia, alpha-glucosidase inhibitors do not cause hypoglycemia. AGIs improve the metabolic profile and potentially lower the risk of long-term hyperglycemia complications in patients with type 2 diabetes mellitus. They can be used alone or with other antihyperglycemic medications and insulin. There are no links to any serious negative consequences. It makes them especially useful for patients with renal, cardiorespiratory, or liver issues, who are at a higher risk of developing lactic acidosis and thus are not good candidates for metformin therapy. They also do not cause hypoglycemia, making them a viable alternative to sulfonylureas, which are frequently associated with hypoglycemia. Patients should be counselled on maintaining an appropriate diet, as a high carbohydrate diet can exacerbate gastrointestinal side effects.
The market is expected to grow during the forecast period due to the factors above.
Asia-Pacific Alpha-Glucosidase Inhibitors Industry Overview
The market studied is highly fragmented into many manufacturers like Bayer, SunPharma, Pfizer, and Takeda, holding a presence in all regions. The Asia-Pacific contributes the highest market share in the current year due to many generic products in the region, especially in China and India.
Asia-Pacific Alpha-Glucosidase Inhibitors Market Leaders
-
Takeda
-
Pfizer
-
Bayer
-
Sun Pharma
-
Glenmark
*Disclaimer: Major Players sorted in no particular order
Asia-Pacific Alpha-Glucosidase Inhibitors Market News
- April 2023: A study was planned to move towards drug repurposing by utilizing Food and Drug Administration (FDA)-approved drugs against α-glucosidase and investigating the molecular mechanisms. The target protein was refined and optimized by introducing missing residues and minimizing to remove clashes to find the potential inhibitor against α-glucosidase.
- July 2022: The Drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) fixed the prices of 84 drug formulations, including those used to treat diabetes. According to the order, a single tablet of Voglibose will cost INR 10.47 (USD 0.13), excluding GST.
Asia-Pacific Alpha-Glucosidase Inhibitors Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 Drug
5.1.1 Alpha-glucosidase Inhibitors
5.2 Geography
5.2.1 Japan
5.2.2 China
5.2.3 South Korea
5.2.4 India
5.2.5 Australia
5.2.6 Malaysia
5.2.7 Indonesia
5.2.8 Philippines
5.2.9 Thailand
5.2.10 Rest of Asia-Pacific
6. MARKET INDICATORS
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Bayer pharma
7.1.2 Takeda
7.1.3 Pfizer
7.1.4 Glenmark pharma
7.1.5 Sun pharma
7.1.6 Torrent
7.1.7 Unichem
7.1.8 Hexalag
- *List Not Exhaustive
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Asia-Pacific Alpha-Glucosidase Inhibitors Industry Segmentation
Alpha-glucosidase inhibitors prevent the small intestine from absorbing carbs. By competitive inhibition, they block enzymes that convert complicated non-absorbable carbs into simple, absorbable carbohydrates. Glucoamylase, sucrase, maltase, and isomaltase are some of these enzymes. The Asia-Pacific Alpha-Glucosidase Inhibitors Market is segmented by geography (Japan, China, South Korea, India, Australia, Vietnam, Malaysia, Indonesia, Philippines, Thailand, and the rest of Asia-Pacific). The report offers the value (in USD) and volume (in units) for the above segments. We will provide a segment-wise breakdown (value and volume) for all the countries covered under the Table of Contents.
| Drug | |
| Alpha-glucosidase Inhibitors |
| Geography | |
| Japan | |
| China | |
| South Korea | |
| India | |
| Australia | |
| Malaysia | |
| Indonesia | |
| Philippines | |
| Thailand | |
| Rest of Asia-Pacific |
Asia-Pacific Alpha-Glucosidase Inhibitors Market Research FAQs
What is the current Asia-Pacific Alpha-Glucosidase Inhibitors Market size?
The Asia-Pacific Alpha-Glucosidase Inhibitors Market is projected to register a CAGR of 2.30% during the forecast period (2024-2029)
Who are the key players in Asia-Pacific Alpha-Glucosidase Inhibitors Market?
Takeda, Pfizer, Bayer, Sun Pharma and Glenmark are the major companies operating in the Asia-Pacific Alpha-Glucosidase Inhibitors Market.
What years does this Asia-Pacific Alpha-Glucosidase Inhibitors Market cover?
The report covers the Asia-Pacific Alpha-Glucosidase Inhibitors Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia-Pacific Alpha-Glucosidase Inhibitors Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
APAC Alpha-Glucosidase Inhibitors Industry Report
Statistics for the 2024 APAC Alpha-Glucosidase Inhibitors market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. APAC Alpha-Glucosidase Inhibitors analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
